rs116840795
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 8P and 4B. PM1PM5PP3_StrongBS2
The NM_033337.3(CAV3):c.169G>A(p.Val57Met) variant causes a missense change. The variant allele was found at a frequency of 0.00000867 in 1,613,994 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V57G) has been classified as Pathogenic.
Frequency
Consequence
NM_033337.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CAV3 | NM_033337.3 | c.169G>A | p.Val57Met | missense_variant | 2/2 | ENST00000343849.3 | NP_203123.1 | |
CAV3 | NM_001234.5 | c.169G>A | p.Val57Met | missense_variant | 2/3 | NP_001225.1 | ||
OXTR | XR_007095681.1 | n.1885-2978C>T | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CAV3 | ENST00000343849.3 | c.169G>A | p.Val57Met | missense_variant | 2/2 | 1 | NM_033337.3 | ENSP00000341940 | P1 | |
CAV3 | ENST00000397368.2 | c.169G>A | p.Val57Met | missense_variant | 2/3 | 1 | ENSP00000380525 | P1 | ||
CAV3 | ENST00000472766.1 | n.155+11590G>A | intron_variant, non_coding_transcript_variant | 2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152156Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251334Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135832
GnomAD4 exome AF: 0.00000889 AC: 13AN: 1461838Hom.: 0 Cov.: 32 AF XY: 0.00000688 AC XY: 5AN XY: 727212
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152156Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74332
ClinVar
Submissions by phenotype
not provided Uncertain:2Other:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 31, 2023 | Identified in a patient with persistently elevated CK levels and reduced CAV3 in sarcolemma of muscle fibers on muscle biopsy; however, he was not otherwise symptomatic for muscular disorder, had a normal ECG, and his mother and brother who were also heterozygous for the variant had persistently elevated CK levels with no muscular symptoms (Alias et al., 2004); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 15564037, 34426522, 27772553, 15099591, 22581547) - |
not provided, no classification provided | curation | Leiden Muscular Dystrophy (CAV3) | Apr 15, 2012 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 20, 2022 | - - |
Long QT syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 09, 2023 | An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Studies have shown that this missense change alters CAV3 gene expression (PMID: 15099591). ClinVar contains an entry for this variant (Variation ID: 31708). This missense change has been observed in individuals with autosomal dominant CAV3-related conditions (PMID: 15099591, 22581547, 26404900, 27772553; Invitae). This variant is present in population databases (rs116840795, gnomAD 0.006%). This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 57 of the CAV3 protein (p.Val57Met). - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Mar 27, 2019 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 20, 2018 | The c.169G>A (p.V57M) alteration is located in exon 2 (coding exon 2) of the CAV3 gene. This alteration results from a G to A substitution at nucleotide position 169, causing the valine (V) at amino acid position 57 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at